All In Biotech

Drug Trial Radar · NCT02607813

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations

Last checked: Nov 20, 2026Latest source record: Dec 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

142

Actual

Start

Jan 18, 2016

Primary completion

Feb 18, 2022

Study completion Feb 19, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.

Conditions

  • NSCLC
  • Ovarian Cancer
  • Melanoma
  • Other Solid Tumors

Interventions

  • LXH254Drug

    pan-RAF inhibitor

  • PDR001Drug

    Biological: PDR001 anti-PD1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity.Time frame: From Cycle 1 Day 1 until 30 days for LXH254 single agent and 150 days for LXH254 in combination with PDR001 post study treatment (expected duration approximately 12 months)
  2. Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 single agent only)Time frame: 28 days
  3. Incidence and nature of dose limiting toxicities (DLTs) (dose escalation and LXH254 in combination with PDR001 only)Time frame: 56 days

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital MGH Cancer Center

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center SC - LXH254X2101

    New York, New York

  • UT M.D Anderson Cancer Center SC - LXH254X2101

    Houston, Texas

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Modena, MO, Italy

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Groningen, Netherlands

  • Medical Oncology, Erasmus MC

    Rotterdam, Netherlands

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.